Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oncolytic Virus T601 +/- 5-FC in Advanced Solid Tumors
NCT04226066Phase 2Unknown
- Sponsor
- Tasly Group
- Start
- Nov 2019
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of TG6002 in advanced malignant solid tumor, gastric cancer (GC), pancreatic cancer (PC), hepatocellular carcinoma (HCC), sponsored by Tasly Group. Status: unknown.
02
Drugs
TG6002
03
Conditions
advanced malignant solid tumorgastric cancer (GC)pancreatic cancer (PC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04226066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226066.